As the biotech community debates Opexa Therapeutics Inc’s (NASDAQ:OPXA) clinical trial setback in Secondary Progressive Multiple Sclerosis (SPMS), Maxim analyst Jason McCarthy added further fuel to …
Friday turned out to be a nightmare for Opexa Therapeutics Inc (NASDAQ:OPXA) investors, after the drug maker announced that its Phase 2b Abili-T clinical trial …
